People: Medivation Inc (MDVN.O)
MDVN.O on Nasdaq
47.41USD
20 May 2013
47.41USD
20 May 2013
Price Change (% chg)
$-0.12 (-0.25%)
$-0.12 (-0.25%)
Prev Close
$47.53
$47.53
Open
$47.64
$47.64
Day's High
$48.84
$48.84
Day's Low
$47.25
$47.25
Volume
1,107,705
1,107,705
Avg. Vol
1,250,893
1,250,893
52-wk High
$59.24
$59.24
52-wk Low
$39.62
$39.62
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Kim Blickenstaff |
59 | 2007 | Independent Chairman of the Board |
David Hung |
54 | 2004 | President, Chief Executive Officer, Director |
C. Patrick Machado |
48 | 2009 | Chief Financial Officer, Chief Business Officer |
Stephen Kelsey |
52 | 2013 | Senior Vice President - New Projects |
Cheryl Cohen |
46 | 2011 | Chief Commercial Officer |
Lynn Seely |
53 | 2005 | Chief Medical Officer |
Kathryn Falberg |
2012 | Director | |
Dawn Graham |
2013 | Director | |
Daniel Adams |
2005 | Independent Director | |
W. Anthony Vernon |
57 | 2006 | Independent Director |
Wendy Yarno |
2013 | Independent Director |
Biographies
| Name | Description |
|---|---|
Kim Blickenstaff |
Mr. Kim D. Blickenstaff is the Independent Chairman of the Board of Medivation, Inc., since 2005. He has served as as the Chairman of the Board since 2007. Mr. Blickenstaff is a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. Mr. Blickenstaff has been President and Chief Executive Officer of Tandem Diabetes Care, a privately held company focusing on improved insulin infusion therapy, since September 2007. From 1988 until August 2007, Mr. Blickenstaff served as Chairman and Chief Executive Officer of Biosite Incorporated, a provider of medical diagnostic products. Mr. Blickenstaff was a director of SenoRx, Inc., a public company that is focused on developing improved breast cancer biopsy and treatment devices from 2002 to 2010, and was a member of its compensation committee. Mr. Blickenstaff was formerly a certified public accountant and has more than 10 years of experience overseeing the preparation of financial statements. Mr. Blickenstaff received a B.A. from Loyola University, Chicago and an M.B.A. from the Graduate School of Business, Loyola University, Chicago. |
David Hung |
Dr. David T. Hung, M.D. has been President, Chief Executive Officer, Director of Medivation, Inc. He is a member of the Board, since December 2004. Previously, Dr. Hung served as the President and Chief Executive Officer, and member of the board of directors, of Medivation Neurology, Inc. from its inception in September 2003 through December 2004, when it became the wholly owned subsidiary by merger. From 1998 until 2001, Dr. Hung was employed by ProDuct Health, Inc., a privately held medical device company, as Chief Scientific Officer (1998-1999) and as President and Chief Executive Officer (1999-2001). Dr. Hung served as a consultant to Cytyc Corporation from 2001 until 2002 to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Hung is a director and member of the compensation committee of Opexa. Dr. Hung received an M.D. from the University of California, San Francisco, School of Medicine, and an A.B. in Biology from Harvard College. Dr. Hung is a co-founder of Medivation, has served as the President and Chief Executive Officer since inception, and is responsible for the overall corporate strategy and selection of the product development candidates. |
C. Patrick Machado |
Mr. C. Patrick Machado, J.D., serves as Chief Financial Officer, Chief Business Officer of Medivation, Inc. Mr. Machado has been the Chief Business Officer since December 2009 and the Chief Financial Officer since December 2004. Previously, Mr. Machado served as the Senior Vice President and Chief Financial Officer, and a member of the Board of Directors, of Medivation Neurology, Inc. from its inception in September 2003 through December 2004, when it became the wholly owned subsidiary by merger. From 1998 until 2001, Mr. Machado was employed by ProDuct Health, Inc., a privately held medical device company, as Vice President, Chief Financial Officer and General Counsel (1998-2000) and as Senior Vice President and Chief Financial Officer (2000-2001). From 2001 until 2002, Mr. Machado served as a consultant to Cytyc Corporation to assist with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Mr. Machado received a J.D. from Harvard Law School and a B.A. and B.S. in German and Economics, respectively, from Santa Clara University. |
Stephen Kelsey |
Dr. Stephen M. Kelsey, M.D., F.R.C.P., F.R.C.Path., is Senior Vice President - New Projects of Medivation, Inc. He joins Medivation from Geron Corporation where he served as the executive vice president, research & development and chief medical officer. From 2009 to 2011 he served as executive vice president and chief medical officer, oncology at Geron. From 2002 to 2009, Dr. Kelsey held various positions at Genentech, Inc., most recently as vice president, clinical hematology/oncology, where he was responsible for the oncology late stage development portfolio including Rituxan(R), Herceptin(R), Tarceva(R), Perjeta(R), Kadcyla(TM), Erivedge(R) and five additional development products in solid tumors and hematologic malignancies. From 2000 to 2002, Dr. Kelsey was the director of clinical affairs at Pharmacia Corporation (SUGEN, Inc.), where he was responsible for Sutent(R), and director of global clinical development (oncology) at Pharmacia Corporation in Milan, Italy. Dr. Kelsey earned his B.Sc. in Pharmacology, M.B., Ch.B., and Doctorate of Medicine (M.D.) degrees from the University of Birmingham in the United Kingdom. |
Cheryl Cohen |
Ms. Cheryl Cohen is the Chief Commercial Officer of Medivation Inc., effective September 2, 2011. From September 2008 to September 2011, Ms. Cohen was president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization, where she was responsible for building strategic and tactical plans to ensure launches. From November 2001 to September 2008 she served as the vice president, strategic commercial group, of Health Care Systems, Inc., a Johnson & Johnson company accountable for managed markets, contracting and supply chain, where she was directly responsible for access of Johnson & Johnson products within one of the health plans in the country. From 1998 to 2007, she worked at Centocor, Inc., a Johnson & Johnson company, in a variety of senior sales roles including vice president, rheumatology franchise, with direct responsibility for the $1+ billion per year Remicade® U.S. rheumatoid arthritis business and its 170-person sales and marketing team. Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions. She received her B.A. from Saint Joseph College. |
Lynn Seely |
Dr. Lynn Seely, M.D. is the Chief Medical Officer of Medivation, Inc. From September 2002 to March 2005, Dr. Seely served as Vice President of Clinical Development at Anesiva, Inc., formerly Corgentech Inc., a biomedical company. From 1996 through 2000, Dr. Seely served as an Associate Director of Clinical Development at Chiron Corporation, a biotechnology company. Dr. Seely served as Vice President of Clinical Development at ProDuct Health, Inc., a privately held medical device company, from 2000 to 2001. Dr. Seely subsequently served as Vice President of Clinical Development for Cytyc Health Corporation, a medical device company and subsidiary of Cytyc Corporation, a medical device company, from 2001 to 2002, where she assisted with transitional matters related to Cytyc Corporation’s acquisition of ProDuct Health, Inc. Dr. Seely received an M.D. from the University of Oklahoma College of Medicine and completed her residency in internal medicine at Yale-New Haven Hospital. |
Kathryn Falberg |
|
Dawn Graham |
|
Daniel Adams |
Mr. Daniel D. Adams is Independent Director of Medivation, Inc., since 2005. Mr. Adams has been the Executive Chairman of Protein Sciences Corporation, a biopharmaceutical company, since 2010 and Chairman of its board of directors since April 2009. He previously served as President and Chief Executive Officer of Protein Sciences Corporation from July 1996 until he became Executive Chairman in 2010. Mr. Adams also was a co-founder and the first Chief Executive Officer of Biogen, and the founder and Chief Executive Officer of Advanced Genetic Sciences, Inc., Plant Genetic Systems and Allerx, Inc. Mr. Adams holds a B.A. in Chemistry from Cornell University and a J.D. magna cum laude from New York University School of Law. |
W. Anthony Vernon |
Mr. W. Anthony Vernon is the Independent Director of Medivation, Inc. He has served at Kraft Foods, Inc., a publicly held food company, as Executive Vice President and President, Kraft Foods of North America since 2009. From 2006 to 2009, Mr. Vernon was the Healthcare Industry Partner at Ripplewood Holdings, Inc., a private equity firm. Mr. Vernon had previously led a number of Johnson & Johnson’s franchises during a 24-year career at Johnson & Johnson, a public company engaged in the research and development, manufacture and sale of products in the health care field. From 2004 until 2005, Mr. Vernon was employed as Company Group Chairman of Depuy Inc., an orthopedics company which is a subsidiary of Johnson & Johnson. From 2001 until 2004, Mr. Vernon served as President and Chief Executive Officer of Centocor, Inc., a biomedicines company which is a division of Johnson & Johnson. He has also served as President of McNeil Consumer Products and Nutritionals, Worldwide President of The Johnson & Johnson-Merck Joint Venture and as a member of Johnson & Johnson’s Group Operating Committees for Consumer Healthcare and Nutritionals, Biopharmaceuticals, and Medical Devices and Diagnostics. He is also a director of several consumer, biotech and medical device companies, including NovoCure Ltd. and Zeo, Inc., and was formerly a director of Uluru Inc., a public specialty pharmaceutical company, from August 2007 to December 2009. Mr. Vernon also serves as a director of the Philadelphia Youth Organization, a non-profit foundation. Mr. Vernon received a B.A. from Lawrence University and an M.B.A. from the Northwestern University Kellogg Graduate School of Management. |
Wendy Yarno |
Mr. Wendy L. Yarno has been appointed as Independent Director of Medivation, Inc., effective April 26, 2013. Mr. Yarno was appointed as a member and chairperson of the Compensation Committee, and a member of the Nominating and Corporate Governance Committee. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Kim Blickenstaff |
-- |
David Hung |
5,592,140 |
C. Patrick Machado |
2,538,780 |
Stephen Kelsey |
-- |
Cheryl Cohen |
3,554,520 |
Lynn Seely |
2,579,030 |
Kathryn Falberg |
-- |
Dawn Graham |
-- |
Daniel Adams |
-- |
W. Anthony Vernon |
-- |
Wendy Yarno |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Kim Blickenstaff |
0 | 0 |
David Hung |
0 | 0 |
C. Patrick Machado |
0 | 0 |
Stephen Kelsey |
0 | 0 |
Cheryl Cohen |
0 | 0 |
Lynn Seely |
150,000 | 1,933,160 |
Kathryn Falberg |
0 | 0 |
Dawn Graham |
0 | 0 |
Daniel Adams |
0 | 0 |
W. Anthony Vernon |
0 | 0 |
Wendy Yarno |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
YARNO WENDY L |
7,500 | $0.00 |
HUNG DAVID T |
1,615 | $55.00 |
GRAHAM DAWN |
7,500 | $0.00 |
HUNG DAVID T |
9,835 | $55.02 |
HUNG DAVID T |
57,465 | $55.13 |
HUNG DAVID T |
200 | $55.00 |
HUNG DAVID T |
50,000 | $52.62 |
HUNG DAVID T |
50,000 | $50.17 |
VERNON WILLIAM ANTHONY |
60,000 | $45.91 |
VERNON WILLIAM ANTHONY |
30,000 | $9.38 |
VERNON WILLIAM ANTHONY |
30,000 | $6.97 |
BLICKENSTAFF KIM DAVID |
13,500 | $47.88 |
BLICKENSTAFF KIM DAVID |
31,300 | $46.92 |
BLICKENSTAFF KIM DAVID |
60,000 | $9.38 |
BLICKENSTAFF KIM DAVID |
15,200 | $46.18 |
FALBERG KATHRYN E |
7,500 | $0.00 |
MACHADO CLARENCE PATRICK |
2,660 | $54.78 |
HUNG DAVID T |
5,315 | $54.78 |
HUNG DAVID T |
4,931 | $54.03 |
MACHADO CLARENCE PATRICK |
2,465 | $54.00 |
SEELY LYNN |
9,000 | $0.00 |
MACHADO CLARENCE PATRICK |
9,000 | $0.00 |
COHEN CHERYL |
9,000 | $0.00 |
HUNG DAVID T |
31,000 | $0.00 |
BAILEY GREGORY H |
24,999 | $11.21 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
